Body fat distribution, insulin sensitivity, ovarian dysfunction and serum lipoproteins in patients with polycystic ovary syndrome

Gynecological Endocrinology

Volumn 16, Issue 1, 2002, Pages 45-51

  Strowitzki, T ^a   Halser, B ^a   Demant, T ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Dyslipidemia; Insulin Resistance; Metabolic Disorders; PCOS

Indexed keywords

ANDROSTENEDIONE; CORTICOTROPIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; NAFARELIN; PROGESTERONE; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY FAT; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOTROPIN TEST; ENDOCRINE DISEASE; FEMALE; HUMAN; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; INSULIN TOLERANCE TEST; LIPOPROTEIN BLOOD LEVEL; METABOLIC DISORDER; OBESITY; OVARY INSUFFICIENCY; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL;

EID: 0036129675     PISSN: 09513590     EISSN: None     Source Type: Journal    
DOI: 10.1080/gye.16.1.45.51     Document Type: Article

References (27)

1. Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: Common and distinct features
2. Insulin sensitivity, insulin secretion, and metabolic and hormonal parameters in healthy women and women with polycystic ovary syndrome
3. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without polycystic ovary syndrome
4. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome
5. Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism
6. Variations of steroid hormone metabolites in serum and urine in polycystic ovary syndrome after nafarelin stimulation: Evidence for an altered corticoid excretion
7. Impact of insulin and body mass index on metabolic and endocrine variables in polycystic ovary syndrome
8. Adipositas - Bedeutung für adoleszenz und reproduktion
9. Nafarelin: A review of its pharmacodynamic and pharmacokinetic properties, and clinical potential in sex hormone-related conditions
10. Bioavailability of nafarelin in healthy volunteers
11. Acne, hirsutism, and alopecia in adolescent girls
12. Detection of functional ovarian hyperandrogenism in women with androgen excess
13. Validation of the low dose short insulin tolerance test for evaluation of insulin sensitivity
14. Body weight, hyperinsulinemia and gonadotropin levels in the polycystic ovary syndrome: Evidence of two distinct populations
15. Insulin, androgens, and obesity in women with and without polycystic ovary syndrome: A heterogeneous group of disorders
16. Insulin sensitivity in women with polycystic ovary syndrome: Relationship to hyperandrogenemia
17. Altered composition of high density lipoproteins in women with the polycystic ovary syndrome
18. Enhanced early insulin resistance in women with polycystic ovary syndrome and normal glucose tolerance
19. Dsylipidaemia is associated with insulin resistance in women with polycystic ovary syndrome
20. Insulin resistance in nonobese patients with polycystic ovarian disease
21. The relative contributions of hepatic and peripheral tissues on insulin resistance in hyperandrogenic women
22. Studies of the nature of 17-hydroxy-progesterone hyperresponsiveness to gonadotropin-releasing hormone agonist challenge in functional ovarian hyperandrogenism
23. Differential activity of the cytochrome P450 17-alpha-hydroxylase and steroidogenic acute regulatory protein gene promoters in normal and polycystic ovary syndrome theca cells
24. Lack of relationship between 17-hydroxy-progesterone response to buserelin testing and hyperinsulinemia in polycystic ovary syndrome
25. Metformin treatment reduces ovarian cytochrome P-450c 17alpha response to human chorionic gonadotrophin in women with insulin resistance-related polycystic ovary syndrome
26. Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catheterization
27. Low-density lipoprotein subclass patterns and risk of myocardial infarction